A number of new β-lactam antibiotics have been developed to overcome bacterial resistance to older agents. Such resistance usually is caused by plasmid-mediated, constituently produced β-lactamases. Second- and third-generation cephalosporins, ureidopenicillins, acylamino penicillins, and monobactams generally are resistant to hydrolysis by these enzymes. However, inducible β-lactamases may confer resistance to these antibiotics. This induction may occur spontaneously or in response to cefoxitin or other β-lactam agents. The mechanisms by which inducible enzymes produce this resistance are reviewed and implications for the prophylactic and therapeutic use of newer β-lactams are considered.
PerkinsRLFassRJWarnerJFCefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients. J Infect Dis1978; 137 (suppl): 110–8.
2.
SandersCCMoelleringRCJrMartinRRResistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis1982; 145: 118–25.
3.
RichmondMHSykesRB. The β-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol1973; 9: 31–88.
4.
LowburyEJLKidsonALillyHAAyliffeGAJJonesRJ. Sensitivity of Pseudomonas aeruginosa to antibiotics: emergence of strains highly resistant to carbenicillin. Lancet1969; 2: 448–52.
5.
HolmesKKClarkHSilverblattFTurckM. Emergence of resistance in Pseudomonas during carbenicillin therapy. Antimicrob Agents Chemother1970; 69: 391–7.
6.
ParryMFNeuHC. Ticarcillin for treatment of serious infections with gram-negative bacteria. J Infect Dis1976; 134: 476–85.
7.
MarierRLMarinaccioATSandersCVAldridgeKEMitchellJW. Susceptibility patterns of bacteria following therapy with piperacillin. J Antimicrob Chemother1982; 9 (suppl B): 85–91.
8.
SimonGLSnydmanDRTallyFPGorbachSL. Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse. Antimicrob Agents Chemother1980; 18: 167–97.
9.
FassRJKusumiRK. Mezlocillin: treatment of skin and soft-tissue infections. J Antimicrob Chemother1982; 9 (suppl): 193–7.
10.
LevineLRMcCainE. Cefamandole in the treatment of infections due to Enterobacter and indole-positive Proteus. J Infect Dis1978; 137 (suppl): 125–32.
11.
NairSRCherubinCE. Use of cefoxitin, a new cephalosporinlike antibiotic, in the treatment of aerobic and anaerobic infections. Antimicrob Agents Chemother1978; 14: 866–75.
PlattREhrlichSLAfarianJO'BrienTFPenningtonJEKassEH. Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother1981; 20: 351–5.
14.
MathisenGEMeyerRDThompsonJMFinegoldSM. Clinical evaluation of moxalactam. Antimicrob Agents Chemother1982; 21: 780–6.
15.
SalzerWPegramPSJrMcCallCE. Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections. Antimicrob Agents Chemother1983; 23: 565–70.
16.
MokhbatJEBrownAEBrookerDCEmergence of resistance to newer β-lactams in Pseudomonas aeruginosa. In: program and abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Las Vegas, NV (abstract 432), 1983.
17.
LandesmanSHCorradoMLShahPMArmengaudMBarzaMCherubinCE. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Am J Med1981; 71: 693–703.
18.
McKendrickMWGeddesAMWiseRBaxR. Cefotaxime in septicemia including typhoid fever. J Antimicrob Chemother1980; 6 (suppl A): 277–81.
19.
ScullyBENeuHC. The use of ceftizoxime in the treatment of critically ill patients infected with multiply antibiotic resistant bacteria. J Antimicrob Chemother1982; 10 (suppl C): 141–50.
20.
BittnerMJDworzackDLPreheimLCTofteRWCrossleyKB. Ceftriaxone therapy of serious bacterial infections in adults. Antimicrob Agents Chemother1983; 23: 261–6.
21.
AronoffSCMurdellDO'BrienCAKungerJDReedMDBlumerJL. Efficacy and safety of ceftriaxone in serious pediatric infections. Antimicrob Agents Chemother1983; 24: 663–6.
BradsherRWSnowRM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med1984; 77/4C: 63–7.
24.
DudekEJQuinnJPLernerSA. Emergence of resistance to β-lactam and aminogl+ycoside antibiotics during cefsulodin therapy of Pseudomonas aeruginosa infections. In: program and abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Las Vegas NV (abstract 431), 1983.
25.
WardleJKSelkonJBInghamHRFreemanR. Ceftazidime in gram-negative infections: three case reports. J Antimicrob Chemother1981; 8 (suppl B): 313–6.
26.
KingAShannonKEykynSPhillipsI. Reduced sensitivity to β-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections. J Antimicrob Chemother1983; 12: 363–70.
27.
FrancioliPClémentMGeroulanosSCeftazidime in severe infections: a Swiss multicenter study. J Antimicrob Chemother1983; 12 (suppl A): 139–46.
28.
BouzaEHellínTSanz-HospitalJRodriguez-CreixemsMLozaEMartinez-BeltránJ. Evaluation of ceftazidime in the treatment of severe bacterial infection. J Antimicrob Chemother1983; 12 (suppl A): 153–9.
29.
EronLJParkCHHixonDLGoldenbergRIPoretzDM. Ceftazidime in patients with Pseudomonas infections. J Antimicrob Chemother1983; 12 (suppl A): 161–9.
30.
PechàreJCDelisleR. Open study of ceftazidime in serious infections due to multiply-resistant bacteria. J Antimicrob Chemother1983; 12 (suppl A): 181–8.
31.
Van DalenRMuytjensHLGimbréreJSF. Ceftazidime treatment in intensive care patients. J Antimicrob Chemother1983; 12 (suppl A): 189–97.
32.
MaslowMJRosenbergAPollockAACeftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother1983; 12 (suppl A): 213–7.
33.
WarrenJWMillerEHFitzpatrickBA randomized, controlled trial of cefoperazone vs. cefamandole-tobramycin in the treatment of putative, severe infections with gram-negative bacilli. Rev Infect Dis1983; 5 (suppl 1): 173–80.
34.
SchentagJJReitbergDPCumboTJ. Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. Am J Med1984; 77 (suppl 6A): 34–42.
35.
DworzackDLBarteltMABaileyRTJrFitzgibbonsRJJrReichJWPicettiGDIII. Emergence of resistance to aztreonam (letter). Clin Pharm1984; 3: 467.
36.
PreheimLCPennRGSandersCCGoeringRVGigerDK. Emergence of resistance during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother1983; 22: 1037–41.
37.
JarlierVPhilipponANicolasMHBismuthRPaulGFusciardiJ. Enterobacter cloacae: emergence in vivo d'un variant resistant aux nouvelles β-lactamines lord d'un traitement par lamoxactam-gentamicine. Pathol Biol1984; 32: 399–403.
38.
WinstonDJBarnesRCHoWGYoungLSChamplinREGaleRP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytic patients. Am J Med1984; 77: 442–50.
39.
GootzTDSandersCCGoeringRV. Resistance to cefamandole: derepression of β-lactamases by cefoxitin and mutation in Enterobacter cloacae. J Infect Dis1982; 146: 34–42.
40.
FindellCMSherrisJC. Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance. Antimicrob Agents Chemother1976; 9: 970–4.
41.
SandersCCSandersWEJrEmergence of resistance to cefamandole: possible role of cefoxitin-inducible β-lactamases. Antimicrob Agents Chemother1979; 15: 792–7.
42.
WashingtonJAII. Discrepancies between in vitro activity of and in vivo response to antimicrobial agents. Diagn Microbiol Infect Dis1983; 1: 25–31.
43.
StoneLLJungkindDL. False-susceptible results from the MS-2 system used for testing resistant Pseudomonas aeruginosa against two third-generation cephalosporins, moxalactam and cefotaxime. J Clin Microbiol1983; 18: 389–94.
44.
NeuHC. The in vitro activity, human pharmacology, and clinical effectiveness of new β-lactam antibiotics. Annu Rev Pharmacol Toxicol1982; 22: 599–642.
45.
SandersCCSandersWEJrSch 29482: comparative activity against Enterobacteriaceae multiply-resistant to β-lactam antibiotics and mycobacteria. J Antimicrob Chemother1982; 9 (suppl C): 59–69.
46.
MinamiSInoueMMitsuhashiS. Purification and properties of a cephalosporinase from Enterobacter cloacae. Antimicrob Agents Chemother1980; 18: 853–7.
47.
SeebergAHTolxdorff-NeutzlingRMWiedemannB. Chromosomal β-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins. Antimicrob Agents Chemother1983; 23: 918–25.
48.
GutmannLWilliamsonR. A model system to demonstrate that β-lactamase-associated antibiotic trapping could be a potential means of resistance. J Infect Dis1983; 148: 316–21.
49.
SandersCCSandersWEJrGoeringRV. In vitro antagonism of β-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother1982; 21: 968–75.
50.
YamamotoTYokotaT. β-lactamase-directed barrier for penicillins of Escherichia coli carrying R plasmids. Antimicrob Agents Chemother1977; 11: 936–40.
51.
ThenRLAngehrnP. Trapping of nonhydrolyzable cephalosporins in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism. Antimicrob Agents Chemother1982; 21: 711–7.
52.
SandersCC. Novel resistance selected by the new expanded spectrum cephalosporins: a concern. J Infect Dis1983; 147: 585–9.
53.
GootzTDSandersCC. Characterization of β-lactamase induction in Enterobacter cloacae. Antimicrob Agents Chemother1983; 23: 91–7.
54.
YotsujiAMinamiSArakiYInoueMMitsuhashiS. Inducer activity of β-lactam antibiotics for the β-lactamases of Proteus rettgeri and Proteus vulgaris. J Antibiot1982; 35: 1590–3.
55.
YoshimuraFNikaidoH. Diffusion of β-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother1985; 27: 84–92.
56.
TomaszA. From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. Rev Infect Dis1979; 1: 434–67.
57.
BushKSykesRB. Interaction of β-lactam antibiotics with β-lactamases as a cause for resistance. In: BryanLE, ed. Antimicrobial drug resistance. New York: Academic Press, 1984: 1–31.
58.
VuHNikaidoH. Role of β-lactam hydrolysis in the mechanism of resistance of a β-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum β-lactams. Antimicrob Agents Chemother1985; 27: 393–8.
GodfreyAJBryanLERabinHR. β-lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment. Antimicrob Agents Chemother1981; 19: 705–11.
61.
MirelmanDNuchamowitzYRubinsteinE. Insensitivity of peptidoglycan biosynthetic reactions to β-lactam antibiotics in a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother1981; 19: 687–95.
62.
GolsteinFWGutmannLWilliamsonRCollatzEAcarJF. In vivo and in vitro emergence of simultaneous resistance to both (3-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens. Ann Microbiol (Inst Pasteur)1983; 134A: 329–37.
63.
ChattopadhyayBHallI. Antagonism between cefoxitin and cefuroxime (letter). J Antimicrob Chemother1979; 5: 490–1.
64.
GoeringRVSandersCCSandersWEJrAntagonism of carbenicillin and cefamandole by cefoxitin in treatment of experimental infections in mice. Antimicrob Agents Chemother1982; 21: 963–7.
65.
KuckNATestaRTForbesM. In vitro and in vivo antibacterial effects of combinations of β-lactam antibiotics. Antimicrob Agents Chemother1981; 19: 634–8.
66.
BennRAVKempRJ. Effect of antibiotic use on the incidence of cephalosporin resistance in two Australian hospitals. J Antimicrob Chemother1984; 14 (suppl B): 71–6.
